The objective of this dissertation was to examine the mutation status of the MDMX gene for patients with ovarian cancer. Therefor the encoded area of the MDMX-gene was sequenced for 118 patients with this kind of cancer. 17 mutations were identified. Overall, the number of mutations is small, which is why it can be assumed, that no oncogene activity is caused by these changes. Furthermore, the already known single nucleotide polymorphism SNP 31112 (T>C, rs2290855) in the intron 9 and SNP 31274 (G>A, rs2290854) in the intron 10 could be detected. Hereto, the clinical data of the patients was evaluated. It becomes apparent that the genetic variants of the MDMX gene influences the age of onset and the survival time particularly of patients with hormone receptor negative tumors. The patients with the changed allele and a hormone receptor negative tumor showed an earlier age of diagnosis and a longer survival time.